Bifidobacteria—Insight into clinical outcomes and mechanisms of its probiotic action

Microbiological Research

Volumn 192, Issue , 2016, Pages 159-171

  Sarkar, Amrita ^a   Mandal, Santanu ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Adverse effects; Clinical application; Combinatorial therapy; Gut microbiome; Immunomodulatory effect; Pathogen protection

Indexed keywords

BACTERIA; METABOLITES; PHYSIOLOGY;

ADVERSE EFFECT; CLINICAL APPLICATION; COMBINATORIAL THERAPY; IMMUNOMODULATORY EFFECTS; MICROBIOME;

PATHOGENS;

ANTIBIOTICS; BACTERIUM; BIOLOGICAL INVASION; CELLS AND CELL COMPONENTS; DIGESTIVE SYSTEM; DISEASE RESISTANCE; IMMUNE RESPONSE; METABOLITE; MICROBIAL COMMUNITY; PATHOGEN; PROBIOTICS;

BIFIDOBACTERIUM;

PROBIOTIC AGENT;

BIFIDOBACTERIALES INFECTIONS; BIFIDOBACTERIUM; CELL WALL; HOMEOSTASIS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; INTESTINE FLORA; INTESTINE MUCOSA; METABOLISM; MICROBIOLOGY; ORGANISMAL INTERACTION; PHYSIOLOGY;

BIFIDOBACTERIALES INFECTIONS; BIFIDOBACTERIUM; CELL WALL; GASTROINTESTINAL MICROBIOME; HOMEOSTASIS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOMODULATION; INTESTINAL MUCOSA; MICROBIAL INTERACTIONS; PROBIOTICS;

EID: 84979082787     PISSN: 09445013     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.micres.2016.07.001     Document Type: Review

References (169)

1. İşlek, A., Sayar, E., Yilmaz, A., Baysan, B.Ö., Mutlu, D., Artan, R., The role of Bifidobacterium lactis B94 plus inulin in the treatment of acute infectious diarrhea in children. Turk. J. Gastroenterol. 25 (2014), 628–633.
2. Akkasheh, G., Kashani-Poor, Z., Tajadadi-Ebrahimi, M., Clinical and metabolic response to probiotic administration in patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. Nutrition 32 (2016), 315–320.
3. Alm, B., Erdes, L., Möllborg, P., et al. Neonatal antibiotic treatment is a risk factor for early wheezing. Pediatrics 121 (2008), 697–702.
4. Alp, G., Aslim, B., Relationship between the resistance to bile salts and low pH with exopolysaccharide (EPS) production of Bifidobacterium spp. isolated from infants feces and breast milk. Anaerobe 16 (2010), 101–105.
5. Alp, G., Aslim, B., Suludere, Z., Akca, G., The role of hemagglutination and effect of exopolysaccharide production on bifidobacteria adhesion to Caco-2 cells in vitro. Microbiol. Immunol. 54 (2010), 658–665.
6. Arrieta, M.C., Bistritz, L., Meddings, J.B., Alterations in intestinal permeability. Gut 55 (2006), 1512–1520.
7. Asarat, M., Apostolopoulos, V., Vasiljevic, T., Donkor, O., Short-chain fatty acids produced by synbiotic mixtures in skim milk differentially regulate proliferation and cytokine production in peripheral blood mononuclear cells, on in peripheral blood mononuclear cells. Int. J. Food Sci. Nutr. 66 (2015), 755–765.
8. Babenko, L.P., Lazarenko, L.M., Shynkarenko, L.M., Mokrozub, V.V., Pidgorskyi, V.S., Spivak, M.J., The effect of lacto- and bifidobacteria compositions on the vaginal microflora in cases of intravaginal staphylococcosis. Mikrobiol Z 74 (2012), 116–125.
9. Bailey, L.C., Forrest, C.B., Zhang, P., Association of antibiotics in infancy with early childhood obesity. JAMA Pediatr. 186 (2014), 1063–1069.
10. Bajaj, B.K., Claes, I.J.J., Lebeer, S., Functional mechanisms of probiotics. J. Microbiol. Biotechnol. Food Sci. 4 (2015), 321–327.
11. Balamurugan, R., Janardhan, H.P., George, S., Chittaranjan, S.P., Ramakrishna, B.S., Bacterial succession in the colon during childhood and adolescence: molecular studies in a southern Indian village. Am. J. Clin. Nutr. 88 (2008), 1643–1647.
12. Bali, V., Panesar, P.S., Bera, M.B., Kennedy, J.F., Bacteriocins: recent trends and potential applications. Crit. Rev. Food Sci. Nutr., 2014, 10.1080/10408398.2012.729231.
13. Becerra, J.E., Coll-Marqués, J.M., Rodríguez-Díaz, J., Monedero, V., Yebra, M.J., Preparative scale purification of fucosyl-N-acetylglucosamine disaccharides and their evaluation as potential prebiotics and antiadhesins. Appl. Microbiol. Biotechnol. 99 (2015), 7165–7176.
14. Bermudez-Brito, M., Plaza-Díaz, J., Muñoz-Quezada, S., Gómez-Llorente, C., Gil, A., Probiotic mechanisms of action. Ann. Nutr. Metab. 61 (2012), 160–174.
15. Bermudez-Brito, M., Muñoz-Quezada, S., Gomez-Llorente, C., et al. Cell-free culture supernatant of Bifidobacterium breve CNCM I-4035 decreases pro-inflammatory cytokines in human dendritic cells challenged with Salmonella typhi through TLR activation. PLoS One 8 (2013), 1–8.
16. Bertelli, C., Pillonel, T., Torregrossa, A., et al. Bifidobacterium longum bacteremia in preterm infants receiving probiotics. Clin. Infect. Dis. 60 (2015), 924–927.
17. Bindels, L.B., Porporato, P., Dewulf, E.M., Gut microbiota-derived propionate reduces cancer cell proliferation in the liver. Br. J. Cancer 107 (2012), 1337–1344.
18. Borriello, S.P., Hammes, W.P., Holzapfel, W., Safety of probiotics that contain lactobacilli or bifidobacteria. Clin. Infect. Dis. 36 (2003), 775–780.
19. Bouhnik, Y., Attar, A., Joly, F.A., Riottot, M., Dyard, F., Flourié, B., Lactulose ingestion increases faecal bifidobacterial counts: a randomised double-blind study in healthy humans. Eur. J. Clin. Nutr. 58 (2004), 462–466.
20. Bourne, K.A., Beebe, J.L., Lue, Y.A., et al. Bacteremia due to Bifidobacterium Eubacterium or Lactobacillus; twenty-one cases and review of the literature. Yale J Biol Med 51 (1978), 505–512.
21. Boyle, R.J., Robins-Browne, R.M., Tang, M.L.K., Probiotic use in clinical practice: what are the risks?. Am. J. Clin. Nutr. 83 (2006), 1256–1264.
22. Braga, T.D., da Silva, G.A.P., de Lira, P.I.C., Lima, M.D.C., Efficacy of Bifidobacterium breve and Lactobacillus casei oral supplementation on necrotizing enterocolitis in very-low-birth-weight preterm infants: a double-blind, randomized, controlled trial. Am. J. Clin. Nutr. 93 (2011), 81–86.
23. Brook, I., Frazier, E.H., Significant recovery of nonsporulating anaerobic rods from clinical specimens. Clin. Infect. Dis. 16 (1993), 476–480.
24. Bush, L.M., De Almeida, K.N.F., Martin, G., Perez, M.T., Probiotic-associated Bifidobacterium septic prosthetic joint arthritis. Infect. Dis. Clin. Pract. 22 (2014), e39–e41.
25. Candela, M., Biagi, E., Centanni, M., et al. Bifidobacterial enolase, a cell surface receptor for human plasminogen involved in the interaction with the host. Microbiology 155 (2009), 3294–3303.
26. Castellazzi, A.M., Valsecchi, C., Caimmi, S., et al. Probiotics and food allergy. Ital. J. Pediatr. 39 (2013), 47–56.
27. Cheikhyoussef, A., Pogori, N., Chen, H., et al. Antimicrobial activity and partial characterization of bacteriocin-like inhibitory substances (BLIS) produced by Bifidobacterium infantis BCRC 14602. Food Control 20 (2009), 553–559.
28. Chenoll, E., Casinos, B., Bataller, E., Novel probiotic Bifidobacterium bifidum CECT 7366 strain active against the pathogenic bacterium Helicobacter pylori. Appl. Environ. Microbiol. 77 (2011), 1335–1343.
29. Chichlowski, M., De Lartigue, G., German, J.B., Raybould, H.E., Mills, D.A., Bifidobacteria isolated from infants and cultured on human milk oligosaccharides affect intestinal epithelial function. J. Pediatr. Gastroenterol. Nutr. 55 (2012), 321–327.
30. Chiu, Y.-H., Tsai, J.-J., Lin, S.-L., Chotirosvakin, C., Lin, M.-Y., Characterisation of bifidobacteria with immunomodulatory properties isolated from human breast milk. J. Funct. Foods 7 (2014), 700–708.
31. Chong, E.S.L., A potential role of probiotics in colorectal cancer prevention: review of possible mechanisms of action. World J. Microbiol. Biotechnol. 30 (2014), 351–374.
32. Collado, M.C., González, A., González, R., Hernández, M., Ferrús, M.A., Sanz, Y., Antimicrobial peptides are among the antagonistic metabolites produced by Bifidobacterium against Helicobacter pylori. Int. J. Antimicrob. Agents 25 (2005), 385–391.
33. Collado, M.C., Hernández, M., Sanz, Y., Production of bacteriocin-like inhibitory compounds by human fecal Bifidobacterium strains. J. Food Prot. 68 (2005), 1034–1040.
34. Collado, M.C., Gueimonde, M., Sanz, Y., Salminen, S., Adhesion properties and competitive pathogen exclusion ability of bifidobacteria with acquired acid resistance. J. Food Prot. 69 (2006), 1675–1679.
35. Davenport, E.R., Mizrahi-Man, O., Michelini, K., et al. Seasonal variation in human gut microbiome composition. PLoS One 9 (2014), 1–10.
36. Delgado, S., O'sullivan, E., Fitzgerald, G., Mayo, B., In vitro evaluation of the probiotic properties of human intestinal Bifidobacterium species and selection of new probiotic candidates. J. Appl. Microbiol. 104 (2008), 1119–1127.
37. Demers, M., Dagnault, A., Desjardins, J., A randomized double-blind controlled trial: impact of probiotics on diarrhea in patients treated with pelvic radiation. Clin. Nutr. 33 (2014), 761–767.
38. Dennis, J.C., Culpepper, T., Nieves, C.J., et al. Probiotics (Lactobacillus gasseri KS-13 bifidobacterium bifidum G9-1, and bifidobacterium longum MM-2) and health-related quality of life in individuals with seasonal allergies. FASEB J. 30 (2016), 916–917.
39. Dilli, D., Aydin, B., Fettah, N.D., The pro pre-save study: effects of probiotics and prebiotics alone or combined on necrotizing enterocolitis in very low birth weight infants. J. Pediatr. 166 (2015), 545–551.
40. Dinleyici, E.C., Dalgic, N., Guven, S., et al. The effect of a multispecies synbiotic mixture on the duration of diarrhea and length of hospital stay in children with acute diarrhea in Turkey: single blinded randomized study. Eur. J. Pediatr. 172 (2013), 459–464.
41. Drago, L., Vecchi, E.D., Gabrieli, A., Grandi, R.D., Toscano, M., Immunomodulatory effects of Lactobacillus salivarius LS01 and Bifidobacterium breve BR03, alone and in combination, on peripheral blood mononuclear cells of allergic asthmatics. Allergy Asthma Immunol. Res. 7 (2015), 409–413.
42. Eichenfield, L.F., Tom, W.L., Berger, T.G., et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J. Am. Acad. Dermatol. 71 (2014), 116–132.
43. El-Soud, N.H.A., Said, R.N., Mosallam, D.S., Baraka, N.A.M., Sabry, M.A., Bifidobacterium lactis in treatment of children with acute diarrhea. A randomized double blind controlled trial. J. Med. Sci. 3 (2015), 403–407.
44. Enomoto, T., Sowa, M., Nishimori, K., Effects of bifidobacterial supplementation to pregnant women and infants in the prevention of allergy development in infants and on fecal microbiota. Allergol. Int. 63 (2014), 575–585.
45. Erdogan, O., Tanyeri, B., Torun, E., et al. The comparition of the efficacy of two different probiotics in rotavirus gastroenteritis in children. J. Trop. Med. 2012 (2012), 1–5.
46. Esko, J.D., Sharon, N., et al. Essentials of glycobiology. Varki, A., Cummings, R.D., Esko, J.D., (eds.) Microbial Lectins: Hemagglutinins, Adhesins, and Toxins, 2nd edition, 2009, Cold Spring Harbor Laboratory Press, Cold Spring Harbor (NY) (Chapter 34).
47. Fanning, S., Hall, L.J., Cronin, M., et al. Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection. PNAS 109 (2012), 2108–2113.
48. Fischer, W., ‘Lipoteichoic acid’ of Bifidobacterium bifidum subspecies pennsylvanicum DSM 20239. Eur. J. Biochem. 165 (1987), 639–646.
49. Fliss, I., Ouwehand, A.C., Kheadr, E., Lahtinen, S., Davids, S.J., Bifidobacteria: genomics and molecular aspects. Mayo, B., van Sinderen, D., (eds.) Antimirobial Activity of the Genus Bifidobacterium, 2010, Caister Academic Press, Norfolk, UK (Chapter 7).
50. Foroni, E., Serafini, F., Amidani, D., Genetic analysis and morphological identification of pilus-like structures in members of the genus Bifidobacterium. Microb. Cell Fact. 10:Suppl 1 (2011), 1–13.
51. Fox, M.J., Ahuja, K.D.K., Robertson, I.K., Ball, M.J., Eri, R.D., Can probiotic yogurt prevent diarrhoea in children on antibiotics? A double-blind, randomised, placebo-controlled study. BMJ Open 5 (2015), 1–6.
52. Fukuda, S., Toh, H., Hase, K., Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 469 (2011), 543–547.
53. Gioia, D.D., Gaggia, F., Baffoni, L., Stenico, V., Beneficial microbes in fermented and functional foods. Rai, V.R., Bai, J.A., (eds.) Role of Bifidobacteria in the Production of Bioactive Compounds and Detoxification of Harmful Compounds, 2014, CRC Press, New York (Chapter 16).
54. Gleinser, M., Grimm, V., Zhurina, D., Yuan, J., Riede, U., Improved adhesive properties of recombinant bifidobacteria expressing the Bifidobacterium bifidum-specific lipoprotein BopA. Microb. Cell Fact. 11 (2012), 1–14.
55. González-Rodríguez, I., Sánchez, B., Ruiz, L., et al. Role of extracellular transaldolase from Bifidobacterium bifidum in mucin adhesion and aggregation. Appl. Environ. Microbiol. 78 (2012), 3992–3998.
56. Groschwitz, K.R., Hogan, S.P., Intestinal barrier function: molecular regulation and disease pathogenesis. J. Allergy Clin. Immunol. 124 (2009), 3–20.
57. Gueimonde, M., Margolles, A., de los Reyes-Gavilán, C.G., Salminen, S., Competitive exclusion of enteropathogens from human intestinal mucus by Bifidobacterium strains with acquired resistance to bile-A preliminary study. Int. J. Food Microbiol. 113 (2007), 228–232.
58. Guglielmetti, S., Tamagnini, I., Mora, D., et al. Implication of an outer surface lipoprotein in adhesion of Bifidobacterium bifidum to caco-2Cells. Appl. Environ. Microbiol. 74 (2008), 4695–4702.
59. Guglielmetti, S., Mora, D., Gschwender, M., Popp, K., Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life-a double-blind, placebo-controlled study. Aliment. Pharmacol. Ther. 33 (2011), 1123–1132.
60. Guglielmetti, S., Zanoni, I., Balzaretti, S., et al. Murein lytic enzyme TgaA of Bifidobacterium bifidum MIMBb75 modulates dendritic cell maturation through its cysteine- and histidine-dependent amidohydrolase/peptidase (CHAP) amidase domain. Appl. Environ. Microbiol. 80 (2014), 5170–5177.
61. Guo, B., Xie, N., Wang, Y., Cooperative effect of Bifidobacteria lipoteichoic acid combined with 5-fluorouracil on hepatoma-22 cells growth and apoptosis. Bull. Cancer 102 (2015), 204–212.
62. Guo, S., Guo, Y., Ergun, A., Lu, L., Walker, W.A., Ganguli, K., Secreted metabolites of Bifidobacterium infantis and Lactobacillus acidophilus protect immature human enterocytes from IL-1β-Induced inflammation: a transcription profiling analysis. PLoS One 10 (2015), 1–19.
63. Ha, G.Y., Yang, C.H., Kim, H., Chong, Y., Case of sepsis caused by Bifidobacterium longum. J. Clin. Microbiol. 37 (1999), 1227–1228.
64. Hata, D., Yoshida, A., Ohkubo, H., et al. Meningitis caused by Bifidobacterium in an infant. Pediatr. Infect. Dis. J. 7 (1988), 669–670.
65. Hidalgo-Cantabrana, C., Sánchez, B., Moine, D., et al. Insights into the ropy phenotype of the exopolysaccharide-Producing strain Bifidobacterium animalis subsp. lactis A1dOxR. Appl. Environ. Microbiol. 79 (2013), 3870–3874.
66. Hidalgo-Cantabrana, C., Nikolic, M., López, P., et al. Exopolysaccharide-producing Bifidobacterium animalis subsp. lactis strains and their polymers elicit different responses on immune cells from blood and gut associated lymphoid tissue. Anaerobe 26 (2014), 24–30.
67. Hidalgo-Cantabrana, C., Sánchez, B., Milani, C., Ventura, M., Margolles, A., Ruas-Madiedo, P., Genomic overview and biological functions of exopolysaccharide biosynthesis in Bifidobacterium spp. Appl. Environ. Microbiol. 80 (2014), 9–18.
68. Hidalgo-Cantabrana, C., Sánchez, B., Álvarez-Martín, P., et al. A single mutation in the gene responsible for the mucoid phenotype of Bifidobacterium animalis subsp. lactis confers surface and functional characteristics. Appl. Environ. Microbiol. 81 (2015), 7960–7968.
69. Hsieh, C.-Y., Osaka, T., Moriyama, E., Date, Y., Kikuchi, J., Tsuneda, S., Strengthening of the intestinal epithelial tight junction by Bifidobacterium bifidum. Physiol. Rep. 3 (2015), 1–17.
70. Hussey, S., Wall, R., Gruffman, E., et al. Parenteral antibiotics reduce bifidobacteria colonization and diversity in neonates. Int. J. Microbiol. 2011 (2011), 1–6.
71. Inturri, R., Stivala, A., Sinatra, F., Morrone, R., Blandino, G., Scanning electron microscopy observation of adhesion properties of Bifidobacterium longum W11 and chromatographic analysis of its exopolysaccaride. Food Nutr. Sci. 5 (2014), 1787–1792.
72. Isidro, R.A., Bonilla, F.J., Pagan, H., et al. The probiotic mixture VSL#3 alters the morphology and secretion profile of both polarized and unpolarized human macrophages in a polarization-dependent manner. J. Clin. Cell Immunol. 5 (2015), 1–20.
73. Jeon, S.G., Kayama, H., Ueda, Y., et al. Probiotic Bifidobacterium breve induces IL-10-producing Tr1Cells in the colon. PLoS Pathog. 8 (2012), 1–15.
74. Jin, J., Zhang, B., Guo, H., Mechanism analysis of acid tolerance response of Bifidobacterium longum subsp. longum BBMN 68 by gene expression profile using RNA-sequencing. PLoS One 7 (2012), 1–18.
75. Jin, J., Zhang, B., Guo, H., et al. Effect of pre-stressing on the acid-stress response in Bifidobacterium revealed using proteomic and physiological approaches. PLoS One 10 (2015), 1–14.
76. Kailasapathy, K., Chin, J., Survival and therapeutic potential of probiotic organisms with reference to Lactobacillus acidophilus and Bifidobacterium spp. Immunol. Cell Biol. 78 (2000), 80–88.
77. Kainulainen, V., Reunanen, J., Hiippala, K., et al. BopA does not have a major role in the adhesion of Bifidobacterium bifidum to intestinal epithelial cells extracellular matrix proteins, and mucus. Appl. Environ. Microbiol. 79 (2013), 6989–6997.
78. Kavanaugh, D.W., O'Callaghan, J., Buttó, L.F., Exposure of Bifidobacterium longum subsp. infantis to milk oligosaccharides increases adhesion to epithelial cells and induces a substantial transcriptional response. PLoS One 8 (2013), 1–13.
79. Kirkali, Z., Rasooly, R., Star, R.A., Rodgers, G.P., Urinary stone disease: progress, status, and needs. Urology 86 (2015), 651–653.
80. Klaenhammer, T.R., Genetics of bacteriocins produced by lactic acid bacteria. FEMS Microbiol. Rev. 12 (1993), 39–86.
81. Kullin, B.R., Reid, S.J., Abratt, V.R., The role of bacteria in urology. Lange, D., Chew, B., (eds.) The Use of Probiotic Bacteria to Treat Recurrent Calcium Oxalate Kidney Stone Disease, 2016, Springer International Publishing, Switzerland (Chapter 7).
82. López, P., Monteserín, D.C., Gueimonde, M., et al. Exopolysaccharide-producing Bifidobacterium strains elicit different in vitro responses upon interaction with human cells. Food Res. Int. 46 (2012), 99–107.
83. Lagier, J.-C., Million, M., Hugon, P., Armougom, F., Raoult, D., Human gut microbiota: repertoire and variations. Front. Cell. Infect. Microbiol. 2 (2012), 1–19.
84. Leahy, S.C., Higgins, D.G., Fitzgerald, G.F., van Sinderen, D., Getting better with bifidobacteria. J. Appl. Microbiol. 98 (2005), 1303–1315.
85. Lebeer, S., Vanderleyden, J., De Keersmaecker, S.C., Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat. Rev. Microbiol. 8 (2010), 171–184.
86. Lebeer, S., Claes, I.J.J., Vanderleyden, J., Anti-inflammatory potential of probiotics: lipoteichoic acid makes a difference. Trends Microbiol. 20 (2012), 5–10.
87. Lee, D.K., Jang, S., Kim, M.J., et al. Anti-proliferative effects of Bifidobacterium adolescentisSPM0212 extract on human colon cancer cell lines. BMC Cancer 8 (2008), 310–318.
88. Lee, I.-C., Tomita, S., Kleerebezem, M., Bron, P.A., The quest for probiotic effector molecules-unraveling strain specificity at the molecular level. Pharmacol. Res. 69 (2013), 61–74.
89. Li, C.-Y., Lin, H.-C., Lai, C.-H., Lu, J.J.-Y., Wu, S.-F., Fang, S.-H., Immunomodulatory effects of Lactobacillus and Bifidobacterium on both murine and human mitogen-activated t cells. Int. Arch. Allergy Immunol. 156 (2011), 128–136.
90. Li-sheng, W., Ling-jia, P., Li, S., Yong, S., Ya-li, Z., Dian-yuan, Z., The apoptosis of experimental colorectal carcinoma cells induced by peptidoglycan of bifidobacterium and the expression of apoptotic regulating genes. Chin. J. Cancer Res. 11 (1999), 184–187.
91. Liu, G., Ren, L., Song, Z., Wang, C., Sun, B., Purification and characteristics of bifidocin A, a novel bacteriocin produced by Bifidobacterium animals BB04 from centenarians' intestine. Food Control 50 (2015), 889–895.
92. Lynch, N.J., Roscher, S., Hartung, T., et al. L-Ficolin specifically binds to lipoteichoic acid, a cell wall constituent of gram-positive bacteria, and activates the lectin pathway of complement. J. Immunol. 172 (2004), 1198–1202.
93. Madsen, K.L., Enhancement of epithelial barrier function by probiotics. J. Epithel. Biol. Pharmacol. 5:Suppl. 1-M8 (2012), 55–59.
94. Mahlen, S.D., Clarridge, J.E., Site and clinical significance of Alloscardovia omnicolens and Bifidobacterium species isolated in the clinical laboratory. J. Clin. Microbiol. 47 (2009), 3289–3293.
95. Margolles, A., Ruas-Madiedo, P., de los Reyes-Gavilán, C.G., Sánchez, B., Gueimonde, M., Molecular detection of human bacterial pathogens. Liu, D., (eds.) Bifidobacterium, 2011, CRC Press, Taylor & Francis, Chapter 5.
96. Marra, F., Lynd, L., Coombes, M., et al. Does antibiotic exposure during infancy lead to development of asthma?: A systematic review and metaanalysis. Chest 129 (2006), 610–618.
97. Martinez, F.A., Balciunas, E.M., Converti, A., Cotter, P.D., de Souza, O.R.P., Bacteriocin production by Bifidobacterium spp. A review. Biotechnol. Adv. 31 (2013), 482–488.
98. Matsuki, T., Pédron, T., Regnault, B., Mulet, C., Hara, T., Sansonetti, P.J., Epithelial cell proliferation arrest induced by lactate and acetate from Lactobacillus casei and Bifidobacterium breve. PLoS One 8 (2013), 1–8.
99. Meneghin, F., Fabiano, V., Mameli, C., Zuccotti, G.V., Probiotics and atopic dermatitis in children. Pharmaceuticals (Basel) 5 (2012), 727–744.
100. Meng, H., Ba, Z., Lee, Y., et al. Consumption of Bifidobacterium animalis subsp. lactis BB-12 in yogurt reduced expression of TLR-2 on peripheral blood-derived monocytes and pro-inflammatory cytokine secretion in young adults. Eur. J. Nutr., 2015, 1–13, 10.1007/s00394-015-1109-5.
101. Minami, J.-i., Kondo, S., Yanagisawa, N., et al. Oral administration of Bifidobacterium breve B-3 modifies metabolic functions in adults with obese tendencies in a randomised controlled trial. J. Nutri Sci. 4 (2015), 1–7.
102. Mitsuoka, T., Bifidobacteria and their role in human health. J. Ind. Microbiol. 6 (1990), 263–268.
103. Moran, J.P., Walter, J., Tannock, G.W., Tonkonogy, S.L., Sartor, R.B., Bifidobacterium animalis causes extensive duodenitis and mild colonic inflammation in monoassociated interleukin-10-deficient mice. Inflamm. Bowel Dis. 15 (2009), 1022–1031.
104. Mortaz, E., Adcock, I.M., Ricciardolo, F.L.M., et al. Anti-inflammatory effects of Lactobacillus rahmnosus and Bifidobacterium breve on cigarette smoke activated human macrophages. PLoS One 10 (2015), 1–17.
105. Motherway, M.O.C., Zomer, A., Leahy, S.C., Functional genome analysis of Bifidobacterium breve UCC2003 reveals type IVb tight adherence (Tad) pili as an essential and conserved host-colonization factor. PNAS 108 (2011), 11217–11222.
106. Muñoz-Quezada, S., Bermudez-Brito, M., Chenoll, E., et al. Competitive inhibition of three novel bacteria isolated from faeces of breast-fed infants against selected enteropathogens. Br. J. Nutr. 109 (2013), S63–S69.
107. Myhre, R., Brantsæter, A.L., Myking, S., et al. Intake of probiotic food and risk of spontaneous preterm delivery. Am. J. Clin. Nutr. 93 (2011), 151–157.
108. Nishihira, J., Kagami-Katsuyama, H., Tanaka, A., Nishimura, M., Kobayashi, T., Kawasaki, Y., Elevation of natural killer cell activity and alleviation of mental stress by the consumption of yogurt containing Lactobacillus gasseri SBT2055 and Bifidobacterium longum SBT2928 in a double-blind, placebo-controlled clinical trial. J. Funct. Foods 11 (2014), 261–268.
109. O'Mahony, L., Mccarthy, J., Kelly, P., et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128 (2005), 541–551.
110. Ohishi, A., Takahashi, S., Ito, Y., et al. Bifidobacterium septicemia associated with postoperative probiotic therapy in a neonate with omphalocele. J. Pediatr. 156 (2010), 679–681.
111. Osman, N., Adawi, D., Molin, G., Ahrne, S., Berggren, A., Jeppsson, B., Bifidobacterium infantis strains with and without a combination of Oligofructose and Inulin (OFI) attenuate inflammation in DSS-induced colitis in rats. BMC Gastroenterol. 6 (2006), 1–10.
112. Picard, C., Fioramonti, J., Francois, A., Robinson, T., Neant, F., Matuchansky, C., Review article: bifidobacteria as probiotic agents −physiological effects and clinical benefits. Aliment. Pharmacol. Ther. 22 (2005), 495–512.
113. Poltavska, O.A., Kovalenko, N.K., Antimicrobial activity of bifidobacterial bacteriocin-like substances. Mikrobiol. Z 74 (2012), 32–42.
114. Presti, I., D'Orazio, G., Labra, M., et al. Evaluation of the probiotic properties of new Lactobacillus and Bifidobacterium strains and their in vitro effect. Appl. Microbiol. Biotechnol. 99 (2015), 5613–5626.
115. Puertollano, E., Kolida, S., Yaqoob, P., Biological significance of short-chain fatty acid metabolism by the intestinal microbiome. Curr. Opin. Clin. Nutr. Metab. Care 17 (2014), 139–144.
116. Ranadheera, C.S., Evans, C.A., Adams, M.C., Baines, S.K., Effect of dairy probiotic combinations on in vitro gastrointestinal tolerance, intestinal epithelial cell adhesion and cytokine secretion. J. Funct. Foods 8C (2014), 18–25.
117. Ring, J., Alomar, A., Bieber, T., et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part I. J. Eur. Acad. Dermatol. Venereol. 26 (2012), 1045–1060.
118. Rodes, L., Khan, A., Paul, A., et al. Effect of probiotics Lactobacillus and Bifidobacterium on gut-derived lipopolysaccharides and inflammatory cytokines: an in vitro study using a human colonic microbiota model. J. Microbiol. Biotechnol. 23 (2013), 518–526.
119. Roger, L.C., Costabile, A., Holland, D.T., Hoyles, L., McCartney, A.L., Examination of faecal Bifidobacterium populations in breast- and formula-fed infants during the first 18 months of life. Microbiology 156 (2010), 3329–3341.
120. Rossi, M., Amaretti, A., Raimondi, S., Folate production by probiotic bacteria. Nutrients 3 (2011), 118–134.
121. Rossi, R., Rossi, L., Fassio, F., Clinical follow-up of 96 patients affected by irritable bowel syndrome treated with a novel multi-strain symbiotic. J. Contemp. Immunol. 2 (2015), 49–58.
122. Ruas-Madiedo, P., Gueimonde, M., Arigoni, F., de los Reyes-Gavilán, C.G., Margolles, A., Bile affects the synthesis of exopolysaccharides by Bifidobacterium animalis. Appl. Environ. Microbiol. 75 (2009), 1204–1207.
123. Sánchez, B., González-Rodríguez, I., de los Reyes Gavilán, C.G., Ruas-Madiedo, P., Margolles, A., Interactive probiotics. Pessione, E., (eds.) Bifidobacteria and Their Interaction with the Gastrointestinal Environment, 2014, CRC Press, New York (Chapter 5).
124. Saez-Lara, M.J., Gomez-Llorente, C., Plaza-Diaz, J., Gil, A., The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials. BioMed Res. Int. 2015 (2015), 1–15.
125. Saggioro, A., Leaky gut microbiota, and cancer: an incoming hypothesis. J. Clin. Gastroenterol. 48 (2014), S62–S66.
126. Salazar, N., Gueimonde, M., Hernandez-Barranco, A.M., Ruas-Madiedo, P., de los Reyes-Gávilan, C.G., Exopolysaccharides produced by intestinal Bifidobacterium strains act as fermentable substrates for human intestinal bacteria. Appl. Environ. Microbiol. 74 (2008), 4737–4745.
127. Salazar, N., López, P., Garrido, P., Immune modulating capability of two exopolysaccharide-producing Bifidobacterium strains in a wistar rat model. BioMed Res. Int. 2014 (2014), 1–9.
128. Salazar, N., Dewulf, E.M., Neyrinck, A.M., et al. Inulin-type fructans modulate intestinal Bifidobacterium species populations and decrease fecal short-chain fatty acids in obese women. Clin. Nutr. 34 (2015), 501–507.
129. Schneewind, O., Missiakas, D., Lipoteichoic acids, phosphate-containing polymers in the envelope of gram-positive bacteria. J. Bacteriol. 196 (2014), 1133–1142.
130. Schwiertz, A., Knauf, M., Pohl, U., Hackel, B., Mueller, H.-J., Effectiveness and tolerability of a synbiotic vaginal suppository for the treatment of bacterial vaginosis. Gynecol. Obstet. 5 (2015), 1–6.
131. Serafini, F., Strati, F., Ruas-Madiedo, P., Evaluation of adhesion properties and antibacterial activities of the infant gut commensal Bifidobacterium bifidum PRL2010. Anaerobe 21 (2013), 9–17.
132. Shen, J., Zuo, Z.-X., Mao, A.-P., Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis crohn's disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm. Bowel Dis. 20 (2014), 21–35.
133. Singh, A., Hacini-Rachinel, F., Gosoniu, M.L., NCC2818 in individuals suffering from seasonal allergic rhinitis to grass pollen: an exploratory, randomized, placebo-controlled clinical trial. Eur. J. Clin. Nutr. 67 (2013), 161–167.
134. Sugahara, H., Odamaki, T., Fukuda, S., Probiotic Bifidobacterium longum alters gut luminal metabolism through modification of the gut microbial community. Sci. Rep. 5 (2015), 1–11.
135. Sultana, R., McBain, A.J., O'Neill, C.A., Strain-dependent augmentation of tight-junction barrier function in human primary epidermal keratinocytes by Lactobacillus and Bifidobacterium lysates. Appl. Environ. Microbiol. 79 (2013), 4887–4894.
136. Suzuki, K., Nishiyama, K., Miyajima, H., Osawa, R., Yamamoto, Y., Muka, T., Adhesion properties of a putative polymorphic fimbrial subunit protein from Bifidobacterium longum subsp longum. Biosci. Microbiota Food Health 35 (2016), 19–27.
137. Tabasco, R., Palencia, P.F.D., Fontecha, J., Peláez, C., Requena, T., Competition mechanisms of lactic acid bacteria and bifidobacteria: fermentative metabolism and colonization. LWT—Food Sci. Technol. 55 (2014), 680–684.
138. Takahashi, S., Anzawa, D., Takami, K., et al. Effect of Bifidobacterium animalis ssp. lactis GCL2505 on visceral fat accumulation in healthy Japanese adults: a randomized controlled trial. Biosci. Microbiota Food Health, 2016 http://org/10.12938/bmfh.2016-002.
139. Tamaki, H., Nakase, H., Inoue, S., Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: a randomized, double-blinded, placebo-controlled multicenter trial. Dig. Endosc. 28 (2016), 67–74.
140. Tejero-Sariñena, S., Barlow, J., Costabile, A., Gibson, G.R., Rowland, I., In vitro evaluation of the antimicrobial activity of a range of probiotics against pathogens: evidence for the effects of organic acids. Anaerobe 18 (2012), 530–538.
141. Toiviainen, A., Jalasvuori, H., Lahti, E., Impact of orally administered lozenges with Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp lactis BB-12 on the number of salivary mutans streptococci, amount of plaque, gingival inflammation and the oral microbiome in healthy adults. Clin. Oral Invest. 19 (2015), 77–83.
142. Tomasik, J., Yolken, R.H., Bahn, S., Dickerson, F.B., Immunomodulatory effects of probiotic supplementation in schizophrenia patients: a randomized, placebo controlled trial. Biomarker Insights 10 (2015), 47–54.
143. Tomoda, A., Kamiya, S., Suzuki, H., Helicobacter pylori and pathogenesis. BioMed Res. Int. 2015 (2015), 1–2.
144. Turroni, F., Peano, C., Pass, D.A., et al. Diversity of bifidobacteria within the infant gut microbiota. PLoS One 7 (2012), 1–12.
145. Turroni, F., Serafini, F., Foroni, E., et al. Role of sortase-dependent pili of Bifidobacterium bifidum PRL2010 in modulating bacterium-host interactions. PNAS 110 (2013), 11151–11156.
146. Turroni, F., Taverniti, V., Ruas-Madiedo, P., et al. Bifidobacterium bifidum PRL2010 modulates the host innate immune response. Appl. Environ. Microbiol. 80 (2014), 730–740.
147. Ulluwishewa, D., Anderson, R.C., McNabb, W.C., Moughan, P.J., Wells, J.M., Roy, N.C., Regulation of tight junction permeability by intestinal bacteria and dietary components. J. Nutr. 141 (2011), 769–776.
148. Uraipan, S., Hongpattarakere, T., Antagonistic characteristics against food-borne pathogenic bacteria of lactic acid bacteria and bifidobacteria isolated from feces of healthy Thai infants. Jundishapur J. Microbiol. 8 (2015), 1–9.
149. Vandenplas, Y., Hert, S.G.D., Probiotical-study group, Randomised clinical trial: the synbiotic food supplement probiotical vs. placebo for acute gastroenteritis in children. Aliment. Pharmacol. Ther. 34 (2011), 862–867.
150. Vazquez-Gutierrez, P., Lacroix, C., Jaeggi, T., Zeder, C., Zimmerman, M.B., Chassard, C., Bifidobacteria strains isolated from stools of iron deficient infants can efficiently sequester iron. BMC Microbiol. 15 (2015), 1–10.
151. Velema, W.A., Szymanski, W., Feringa, B.L., Photopharmacology: beyond proof of principle. J. Am. Chem. Soc. 136 (2014), 2178–2191.
152. Ventura, M., Turroni, F., van Sinderen, D., Diet-Microbe interactions in the gut: effects on human health and disease. Tuohy, K., Rio, D.D., (eds.) Bifidobacteria of the Human Gut: Our Special Friends, 2014, Academic Press, Elsevier, USA (Chapter 4).
153. 1A. Microb. Infect., 2015, 1–10, 10.1016/j.micinf.2015.10.008.
154. Vitaliti, G., Pavone, P., Guglielmo, F., Spataro, G., Falsaperla, R., The immunomodulatory effect of probiotics beyond atopy: an update. J. Asthma 51 (2014), 320–332.
155. Vuyst, L.D., Leroy, F., Cross-feeding between bifidobacteria and butyrate-producing colon bacteria explains bifidobacterial competitiveness, butyrate production, and gas production. Int. J. Food Microbiol. 149 (2011), 73–80.
156. Wang, H., Edwards, M.A., Falkinham, J.O., Pruden, A., Probiotic approach to pathogen control in premise plumbing systems? A review. Environ. Sci. Technol. 47 (2013), 10117–10128.
157. Weber, E., Reynaud, Q., Suy, F., Bifidobacterium species bacteremia: risk factors in adults and infants. Clin. Infect. Dis. 61 (2015), 482–484.
158. Wickramasinghe, S., Pacheco, A.R., Lemay, D.G., Mills, D.A., Bifidobacteria grown on human milk oligosaccharides downregulate the expression of inflammation-related genes in Caco-2 cells. BMC Microbiol. 15 (2015), 172–184.
159. Wilson, R.W., Martin, W.J., Wilkowske, C.J., Anaerobic bacteremia. Mayo Clin. Proc. 47 (1972), 639–646.
160. Wollenberg, A., Oranje, A., Deleuran, M., ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J. Eur. Acad. Dermatol. Venereol. 30 (2016), 729–747.
161. Wu, M.-H., Pan, T.-M., Wu, Y.-J., Chang, S.-J., Chang, M.-S., Hu, C.-Y., Exopolysaccharide activities from probiotic bifidobacterium: immunomodulatory effects (on J774A.1 macrophages) and antimicrobial properties. Int. J. Food Microbiol. 144 (2010), 104–110.
162. Xie, N., Wang, Y., Wang, Q., Li, F.r., Guo, B., Lipoteichoic acid of Bifidobacterium in combination with 5-fluorouracil inhibit tumor growth and relieve the immunosuppression. Bull. Cancer 99 (2012), E55–E63.
163. Yang, X., Hang, X., Tan, J., Yang, H., Differences in acid tolerance between Bifidobacterium breveBB8 and its acid-resistant derivative B breve BB8dpH, revealed by RNA-sequencing and physiological analysis. Anaerobe 33 (2015), 76–84.
164. Yasmin, A., Butt, M.S., Afzaal, M., Baak, M.V., Nadeem, M.T., Shahid, M.Z., Prebiotics, gut microbiota and metabolic risks: unveiling the relationship. J. Funct. Foods 17 (2015), 189–201.
165. Yoon, J.S., Sohn, W., Lee, O.Y., Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J. Gastroenterol. Hepatol. 29 (2014), 52–59.
166. Zanotti, I., Turroni, F., Piemontese, A., Evidence for cholesterol-lowering activity by Bifidobacterium bifidum PRL2010 through gut microbiota modulation. Appl. Microbiol. Biotechnol. 99 (2015), 6813–6829.
167. Zhang, C.Y., Chen, G.F., Wang, Y.Y., Xu, Z., Wang, Y.G., Song, X.L., A3α-peptidoglycan extracted from Bifidobacterium sp: could enhance immunological ability of Apostichopus japonicas. Aquacult. Nutr. 21 (2015), 679–689.
168. Zihler, A., Blay, G.L., Chassard, C., Braegger, C.P., Lacroix, C., Bifidobacterium thermophilum RBL67 inhibits salmonella enterica serovar typhimurium in an In vitro intestinal fermentation model. J. Food Nutr. Disord. S1-003 (2014), 1–10.
169. d'Ettorre, G., Ceccarelli, G., Giustini, N., et al. Probiotics reduce inflammation in antiretroviral treated, HIV-infected individuals: results of the probio-HIV clinical trial. PLoS One 10 (2015), 1–15.